NCT02440230View on ClinicalTrials.gov

Safety of OFS Combined With AI Endocrine Therapy in Chinese Premenopausal Breast Cancer Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2021

Conditions
Breast Cancer
Interventions
DRUG

OFS + Anastrozole

"Ovarian function suppression can be achieved by choice of goserelin at a dose of 3.6 mg administered by means of subcutaneous injection every 28 days,bilateral oophorectomy,or bilateral ovarian irradiation.~Patients will take anastrozole 1mg qd."

DRUG

OFS + Exemestane

Patients will take exemestane 25mg qd. Ovarian function suppression can be achieved by choice of goserelin at a dose of 3.6 mg administered by means of subcutaneous injection every 28 days,bilateral oophorectomy,or bilateral ovarian irradiation.

Trial Locations (1)

200025

Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai

All Listed Sponsors
lead

Shanghai Jiao Tong University School of Medicine

OTHER

NCT02440230 - Safety of OFS Combined With AI Endocrine Therapy in Chinese Premenopausal Breast Cancer Patients | Biotech Hunter | Biotech Hunter